The FDA announced today that it is permitting the restricted use of Zelnorm (tegaserod maleate) under a treatment investigational new drug (IND) protocol to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in women younger than 55 who meet strict criteria and have no known or pre-existing heart problems and are in critical need of this drug.Sometimes when no comparable or satisfactory alternative drug or therapy is available, the FDA will allow...
